B-cell Leukemia
📧 Sign up to get email alerts when something new happens for B-cell Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-08Clinical Trial Update: Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation [Phase 1]
This Phase 1 trial evaluated donor-derived anti-CD19 CAR-T cells in patients with recurrent or persistent B-cell malignancies after allogene…
-
CLINICAL_TRIALS research · 2026-04-03Clinical Trial Update: CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies [Phase 1]
A Phase 1 study of CLIC-2201 for relapsed/refractory B-cell malignancies is currently recruiting. The conditions covered include various B-c…
-
CLINICAL_TRIALS research · 2026-01-20Clinical Trial Update: Universal CAR-T Cells (REVO-UWD-19) for Refractory and Relapsed B-Cell Tumors [EARLY_Phase 1]
A Phase 1 trial evaluating universal CAR-T cells (REVO-UWD-19) for refractory or relapsed B-cell malignancies is currently recruiting, spons…
-
CLINICAL_TRIALS research · 2026-01-13Clinical Trial Update: A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies [Phase 1]
MacroGenics reports a Phase 1 study of MGD024 in relapsed or refractory hematologic malignancies is currently recruiting across multiple dis…
-
CLINICAL_TRIALS research · 2025-12-24Clinical Trial Update: Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial) [Phase 1]
This Clinical Trial Update describes BaseCAR-01, a Phase 1 study evaluating bispecific CAR T cells in B-cell malignancies, with recruitment …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2025-12-12Clinical Trial Update: CD22 Redirected Autologous T Cells for ALL [Phase 1]
Phase 1 clinical trial update on autologous T cells redirected to CD22 for B-cell leukemias and lymphomas, sponsored by the University of Pe…
-
CLINICAL_TRIALS research · 2025-12-01Clinical Trial Update: Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell Studies
Clinical trial update describing a follow-up protocol for individuals previously enrolled in CAR-T cell studies, detailing a gene therapy fo…
-
CLINICAL_TRIALS trial_result · 2025-10-30Clinical Trial Update: Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. [Phase 4]
This Phase 4 trial update describes extending ibrutinib treatment for patients who continue to benefit from the therapy.
-
CLINICAL_TRIALS research · 2025-02-19Clinical Trial Update: CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating CAR2219 CAR-T cells for relapsed or refractory B-cell leukemia and B-cell lymphoma is currently recrui…
-
CLINICAL_TRIALS trial_result · 2024-08-20Clinical Trial Update: CD19-CAR-T2 Cells for CD19 Positive B Cell Malignancies [Phase 2]
This update announces the completion of a Phase 2 trial evaluating CD19-CAR-T2 cells for CD19-positive B-cell malignancies, including B-cell…
-
CLINICAL_TRIALS trial_result · 2023-07-11Clinical Trial Update: A Study of Novel Anti-CD19 CAR-T in Patients With r/r B-Cell Malignancies [Phase 1, Phase 2]
Phase 1/2 study evaluating a novel anti-CD19 CAR-T therapy in patients with relapsed/refractory B-cell malignancies (leukemia and lymphoma).
-
CLINICAL_TRIALS trial_result · 2023-04-18Clinical Trial Update: CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma [Phase 1, Phase 2]
Phase 1/2 trial updating CAR-T therapy targeting CD19 and CD22 for relapsed/refractory B-cell leukemia and lymphoma.
-
CLINICAL_TRIALS trial_result · 2021-10-20Clinical Trial Update: CD19-targeting, 3rd Generation CAR T Cells for Refractory B Cells Malignancy [Phase 2]
Phase 2 trial update of CD19-targeting, 3rd generation CAR T cells for refractory B-cell malignancies has completed.
-
CLINICAL_TRIALS trial_result · 2021-02-10Clinical Trial Update: Induced-T Cell Like NK Cells for B Cell Malignancies [Phase 1, Phase 2]
A clinical trial update for induced-T cell like NK cells targeting B cell malignancies is underway in Phase 1/Phase 2, with unspecified curr…
-
CLINICAL_TRIALS trial_result · 2020-03-23Clinical Trial Update: Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma [Phase 1, Phase 2]
Phase I/IIA study of CART19 cells in chemotherapy-resistant or refractory CD19+ leukemia and lymphoma completed; results posted.
-
CLINICAL_TRIALS research · 2018-07-02Clinical Trial Update: CD19-targeted CAR-T Cell Therapy for MRD+ B-cell Malignancies After Autologous Stem Cell Transplantation [NA]
This clinical trial update discusses a CD19-targeted CAR-T cell therapy approach for minimal residual disease–positive B-cell lymphoma or le…
-
CLINICAL_TRIALS trial_result · 2018-03-13Clinical Trial Update: A Feasibility and Safety Study of Concomitant Therapy With Allo-CAR-T Cells and Allo-HSCT in Patients With Relapse or Refractory Leukemia [Phase 1]
This clinical trial update covers a Phase 1 feasibility and safety study evaluating concomitant therapy with allogeneic CAR-T cells and allo…
-
CLINICAL_TRIALS trial_result · 2018-01-16Clinical Trial Update: A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma [Phase 1, Phase 2]
A feasibility and safety study evaluating universal dual-specificity CAR-T cells targeting CD19/CD20 or CD22 for relapsed or refractory B ce…
-
CLINICAL_TRIALS trial_result · 2017-10-30Clinical Trial Update: CD19-targeting 3rd Generation CAR T Cells for Refractory B Cell Malignancy - a Phase I/IIa Trial. [Phase 1, Phase 2]
A Phase I/IIa trial evaluating CD19-targeting third-generation CAR T cells for refractory B-cell malignancies has completed.
-
CLINICAL_TRIALS research · 2017-06-23Clinical Trial Update: A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma [Phase 1, Phase 2]
Clinical trial update on UCART019 for relapsed/refractory CD19+ leukemia and lymphoma (Phase 1/2) conducted by Chinese PLA General Hospital.
-
CLINICAL_TRIALS research · 2017-04-28Clinical Trial Update: CAR T Cells for Refractory B Cell Malignancy [Phase 1, Phase 2]
This entry reports an ongoing Phase 1/Phase 2 trial of CAR T cell therapy for refractory B-cell malignancies, including B-cell leukemia and …
-
CLINICAL_TRIALS trial_result · 2016-10-14Clinical Trial Update: CD19-redirected Autologous Cells (CAR-CD19 T Cells) [Phase 1]
Phase 1 clinical trial update on autologous CAR-CD19 T cells targeting CD19-positive malignant B-cell leukemia and lymphoma.
-
CLINICAL_TRIALS research · 2016-06-28Clinical Trial Update: Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed B Cell Hematologic Malignancies [NA]
Clinical trial update regarding Chimeric Antigen Receptor T Cells (CART) therapy for refractory/relapsed B-cell hematologic malignancies.
-
CLINICAL_TRIALS trial_result · 2016-01-01Clinical Trial Update: Immunotherapy Using Autologous T Cell-Engineered With CD19-specific Chimeric Antigen Receptor for the Treatment of Recurrent /Refractory B Cell Leukemia [Phase 1, Phase 2]
This clinical trial update describes an autologous CD19-directed CAR-T cell therapy for recurrent or refractory B-cell leukemia in Phase 1/2…
-
CLINICAL_TRIALS trial_result · 2013-05-22Clinical Trial Update: Study of the Safety and Tolerability of PCI-32765 in Patients With Recurrent B Cell Lymphoma [Phase 1]
Phase 1 study assessing the safety and tolerability of PCI-32765 (ibrutinib) in patients with recurrent B-cell lymphoma or B-cell leukemia; …